Shuttle Pharmaceuticals Holdings, Inc. Logo

Shuttle Pharmaceuticals Holdings, Inc.

Develops drugs to enhance radiation therapy for cancer and offers predictive diagnostics.

SHPH | US

Overview

Corporate Details

ISIN(s):
US8256933024
LEI:
Country:
United States of America
Address:
401 PROFESSIONAL DRIVE, 20879 GAITHERSBURG
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to improving outcomes for cancer patients by enhancing the effectiveness of radiation therapy (RT). The company develops novel therapies designed to sensitize cancer cells to radiation while protecting healthy tissues. Its lead product candidate, Ropidoxuridine, is a Phase II clinical-stage oral radiation sensitizer. The development pipeline also includes a portfolio of pre-clinical selective histone deacetylase (HDAC) inhibitors. In addition to therapeutics, Shuttle Pharma is developing diagnostic technologies, such as predictive blood tests for prostate cancer patients, to inform therapeutic decision-making and patient management. The company utilizes a proprietary drug discovery platform and strategic collaborations to advance its mission of increasing cancer cure rates and improving patient quality of life.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Shuttle Pharmaceuticals Holdings, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shuttle Pharmaceuticals Holdings, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shuttle Pharmaceuticals Holdings, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

co.don AG Logo
Develops personalized cartilage cell transplants for minimally invasive joint repair.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.
United States of America
COEP
COGNITION THERAPEUTICS INC Logo
Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.
United States of America
CGTX
Coherus Oncology, Inc. Logo
Commercial-stage biopharma developing immuno-oncology therapies for hard-to-treat cancers.
United States of America
CHRS
COLLEGIUM PHARMACEUTICAL, INC Logo
Develops and commercializes abuse-deterrent medications for responsible chronic pain management.
United States of America
COLL
CollPlant Biotechnologies Ltd Logo
Develops rhCollagen for 3D bioprinting of tissues for regenerative & aesthetic medicine.
United States of America
CLGN
Compass Therapeutics, Inc. Logo
A clinical-stage oncology firm developing antibody therapies that engage the immune system.
United States of America
CMPX
Compugen Ltd. Logo
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
Israel
CGEN
COMPUGEN LTD Logo
AI-driven discovery of novel cancer immunotherapies for treatment-resistant patients.
United States of America
CGEN
Connect Biopharma Holdings Ltd Logo
Develops immune modulators for T cell-driven inflammatory diseases like asthma and COPD.
United States of America
CNTB

Talk to a Data Expert

Have a question? We'll get back to you promptly.